https://www.selleckchem.com/pr....oducts/seclidemstat.
Intention-to-treat analysis demonstrated that the two therapies had comparable eradication rate (95.2% vs 93.5%; 95% confidence interval, -4.0% ~ 7.4%; P = 0.582). However, reverse hybrid therapy had a much lower frequency of adverse events than concomitant therapy (20.2 % vs. 38.7%, P = 0.001). The two therapies exhibited comparable drug adherence (93.5% vs 87.9%, P = 0.125). CONCLUSIONS 14-day reverse hybrid therapy and 14-day concomitant therapy are equivalent in efficacy for the first-line treatment of H pylori infection. Howev